FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports
22/06/2026 11:54
FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports June 22 (Reuters) - The U.S. Food and Drug Administration will reverse its earlier rejection of a rare-disease therapy from Regenxbio RGNX.O, the Wall Street Journal reported on Monday.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Diti Pujara)
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics